[F12. Antiparasitic agents U.K.
2.1. Agents acting against endoparasites U.K.
2.1.1. Salicylanilides U.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Closantel | Closantel | Bovine | 1 000 μg/kg | Muscle | |
3 000 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
3 000 μg/kg | Kidney | ||||
Ovine | 1 500 μg/kg | Muscle | |||
2 000 μg/kg | Fat | ||||
1 500 μg/kg | Liver | ||||
5 000 μg/kg | Kidney | ||||
[F2Rafoxanide | Rafoxanide | Bovine | 30 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
30 μg/kg | Fat | ||||
10 μg/kg | Liver | ||||
40 μg/kg | Kidney | ||||
Ovine | 100 μg/kg | Muscle | |||
250 μg/kg | Fat | ||||
150 μg/kg | Liver | ||||
150 μg/kg | Kidney] |
Textual Amendments
F2 Inserted by Commission Regulation (EC) No 1478/2001 of 18 July 2001 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
2.1.2. Tatra-hydro-imidazoles (imidazolthiazoles) U.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Levamisole | Levamisole | Bovine, ovine, porcine, poultry | 10 μg/kg | Muscle | |
10 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
10 μg/kg | Kidney |
2.1.3. Benzimidazoles and pro-benzimidazoles U.K.
a [F3Not for use in animals producing milk for human consumption.] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F4Albendazole | Sum of albendazole sulphoxide, albendazole sulphone, and albendazole 2-amino sulphone, expressed as albendazole | All ruminants | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
500 μg/kg | Kidney | ||||
100 μg/kg | Milk] | ||||
[F5Albendazole oxide | Sum of albendazole oxide, albendazole sulphone and albendazole 2-aminosulphone, expressed as albendazole | Bovine, ovine | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
500 μg/kg | Kidney | ||||
100 μg/kg | Milk | ] | |||
[F4Febantel | Sum of extractable residues which may be oxidised to oxfendazole sulphone | All ruminants | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
10 μg/kg | Milk | ||||
Fenbendazole | Sum of extractable residues which may be oxidised to oxfendazole sulphone | All ruminants | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
10 μg/kg | Milk] | ||||
[F6Flubendazole | Sum of flubendazole and (2-amino 1H-benzimidazol-5-yl) (4fluorophenyl) methanone | Poultry, porcine | 50 μg/kg | Muscle | |
50 μg/kg | Skin + fat | ||||
400 μg/kg | Liver | ||||
300 μg/kg | Kidney | ||||
Flubendazole | Flubendazole | Poultry | 400 μg/kg | Eggs | ] |
[F7Mebendazole | Sum of mebendazole methyl (5-(1-hydroxy, 1-phenyl) methyl-1H-benzimidazol-2-yl) carbamate and (2-amino-1H-benzimidazol-5-yl) phenylmethanone, expressed as mebendazole equivalents | Ovine, caprine, equidae | 60 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
60 μg/kg | Fat | ||||
400 μg/kg | Liver | ||||
60 μg/kg | Kidney] | ||||
[F8Netobimin | Sum of albendazole oxide, albendazole sulphone and albendazole 2-aminosulphone, expressed as albendazole | [X1Bovine, ovine] | 100 μg/kg | Muscle | For oral use only |
100 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
500 μg/kg | Kidney | ||||
100 μg/kg | Milk] | ||||
[F4Oxfendazole | Sum of extractable residues which may be oxidised to oxfendazole sulphone | All ruminants | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
10 μg/kg | Milk] | ||||
Oxibendazole | Oxibendazole | Porcine | 100 μg/kg | Muscle | |
500 μg/kg | Skin and fat | ||||
200 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
[F4Thiabendazole | Sum of thiabendazole and 5-hydroxythiabendazole | Caprine | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
100 μg/kg | Milk] | ||||
[F9Triclabendazole | Sum of extractable residues that may be oxidised to ketotriclabendazole | All ruminants a | 225 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
250 μg/kg | Liver | ||||
150 μg/kg | Kidney] |
Editorial Information
X1 Substituted by Corrigendum to Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 118 of 27 April 2001).
Textual Amendments
F3 Inserted by Commission Regulation (EC) No 1729/2006 of 23 November 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards firocoxib and triclabendazole (Text with EEA relevance).
F4 Substituted by Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F5 Inserted by Commission Regulation (EC) No 2393/1999 of 11 November 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F6 Substituted by Commission Regulation (EC) No 1055/2006 of 12 July 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards flubendazole and lasalocid (Text with EEA relevance).
F7 Inserted by Commission Regulation (EC) No 1680/2001 of 22 August 2001 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F8 Inserted by Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F9 Substituted by Commission Regulation (EC) No 1729/2006 of 23 November 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards firocoxib and triclabendazole (Text with EEA relevance).
[F102.1.4. Phenol derivatives including salicylanides U.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Nitroxinil | Nitroxinil | Bovine, ovine | 400 μg/kg | Muscle | |
200 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
400 μg/kg | Kidney | ||||
[F4Oxyclozanide | Oxyclozanide | All ruminants | 20 μg/kg | Muscle | |
20 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
10 μg/kg | Milk] ] |
Textual Amendments
F10 Inserted by Commission Regulation (EC) No 997/1999 of 11 May 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F112.1.5. Benzenesulphonamides U.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Clorsulon | Clorsulon | Bovine | 35 μg/kg | Muscle | |
100 μg/kg | Liver | ||||
200 μg/kg | Kidney | ] |
Textual Amendments
F11 Inserted by Commission Regulation (EC) No 1942/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F122.1.6. Piperazine derivatives U.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Piperazine | Piperazine | Porcine | 400 μg/kg | Muscle | |
800 μg/kg | Skind and fat | ||||
2 000 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ||||
Chicken | 2 000 μg/kg | Eggs | ] |
Textual Amendments
F12 Inserted by Commission Regulation (EC) No 868/2002 of 24 May 2002 amending Annexes I and II of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F132.1.7. Tetrahydropyrimides U.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Morantel | Sum of residues which may be hydrolysed to N-methyl-1,3- propanediamine and expressed as morantel equivalents | Bovine, ovine | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
800 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
[F14All ruminants | 100 μg/kg | Muscle | |||
100 μg/kg | Fat | ||||
800 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
50 μg/kg | Milk | ] ] |
Textual Amendments
F14 Inserted by Commission Regulation (EC) No 1356/2005 of 18 August 2005 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards oxolinic acid and morantel (Text with EEA relevance).
Textual Amendments
F13 Inserted by Commission Regulation (EC) No 1851/2004 of25 October 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits for veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F152.1.8. Others U.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Monepantel | Monepantel-sulfone | Ovine | 700 μg/kg | Muscle | Not for use in animals producing milk for human consumption |
7 000 μg/kg | Fat | ||||
5 000 μg/kg | Liver | ||||
2 000 μg/kg | Kidney] |
Textual Amendments
F15 Inserted by Commission Regulation (EC) No 478/2009 of 8 June 2009 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards monepantel (Text with EEA relevance).
2.2. Agents acting against ectoparasites U.K.
2.2.1. Organophosphates U.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F2Coumafos | Coumafos | Bees | 100 μg/kg | Honey | ] |
Diazinon | Diazinon | Bovine, ovine, caprine | 20 μg/kg | Milk | |
Bovine, porcine, ovine, caprine | 20 μg/kg | Muscle | |||
700 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
[F8Phoxim | Phoxim | Ovine | 50 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
400 μg/kg | Fat | ||||
50 μg/kg | Kidney | ||||
Porcine | 20 μg/kg | Muscle | |||
700 μg/kg | Skin and fat | ||||
20 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
[F16Chicken | 25 μg/kg | Muscle | |||
550 μg/kg | Skin + fat | ||||
50 μg/kg | Liver | ||||
30 μg/kg | Kidney | ||||
60 μg/kg | Eggs | ] ] |
Textual Amendments
F16 Inserted by Commission Regulation (EC) No 1299/2005 of 8 August 2005 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards phenoxymethylpenicillin, phoxim, norgestomet and thiamphenicol (Text with EEA relevance).
2.2.2. Formamidines U.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Amitraz | Sum of amitraz and all metabolites containing the 2,4-DMA moiety, expressed as amitraz | Bovine | 200 μg/kg | Fat | |
200 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
10 μg/kg | Milk | ||||
Ovine | 400 μg/kg | Fat | |||
100 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
10 μg/kg | Milk | ||||
Porcine | 400 μg/kg | Skin and fat | |||
200 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
[F5 | Bees (honey) | 200 μg/kg | Honey | ] | |
[F17 | Caprine | 200 μg/kg | Fat | ||
100 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
10 μg/kg | Milk | ] |
Textual Amendments
F17 Inserted by Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
2.2.3. Pyrethroids U.K.
a [F18Further provisions in Commission Directive 98/82/EC are to be observed ( OJ L 290, 29.10.1998, p. 25 ).] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F8 [X1Cyhalothrin | Cyhalothrin (sum of isomers) | Bovine | 500 μg/kg | Fat | Further provisions in Council Directive 94/29/EC are to be observed |
50 μg/kg | Kidney | ||||
50 μg/kg | Milk] ] | ||||
[F8 [X2Cyfluthrin | Cyfluthrin (sum of isomers) | Bovine, caprine | 50 μg/kg | Fat | |
10 μg/kg | Liver | ||||
10 μg/kg | Kidney | ||||
20 μg/kg | Milk | Further provisions in Council Directive 94/29/EC are to be observed] ] | |||
[F19 [F4Deltamethrin | Deltamethrin | All ruminants | 10 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
10 μg/kg | Liver | ||||
10 μg/kg | Kidney | ||||
20 μg/kg | Milk] | ||||
[F20Fin fish | 10 μg/kg | Muscle and skin in natural proportions] ] | |||
[F21Fenvalerate | Fenvalerate (sum of RR, SS, RS and SR isomers) | Bovine | 25 μg/kg | Muscle | |
250 μg/kg | Fat | ||||
25 μg/kg | Liver | ||||
25 μg/kg | Kidney | ||||
40 μg/kg | Milk] | ||||
Flumethrin | Flumethrin (sum of trans-Z isomers) | Bovine | 10 μg/kg | Muscle | |
150 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
10 μg/kg | Kidney | ||||
30 μg/kg | Milk | ||||
[F22 | Ovine | 10 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption | |
150 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
10 μg/kg | Kidney | ] | |||
[F18Permethrin | Permethrin (sum of isomers) | Bovine | 50 μg/kg | Muscle | |
500 μg/kg | Fat | ||||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
50 μg/kg | Milk a | ] | |||
[F23Cypermethrin | Cypermethrin (sum of isomers) | Salmonidae | 50 μg/kg | Muscle and skin in natural proportions | ] |
[F4All ruminants | 20 μg/kg | Muscle | |||
200 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
20 μg/kg | Milk a | ] | |||
[F24Alphacypermethrin | Cypermethrin (sum of isomers) | Bovine, ovine | 20 μg/kg | Muscle | |
200 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
20 μg/kg | Milk] a |
Editorial Information
X2 Substituted by Corrigendum to Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Union L 118 of 27 April 2001).
Textual Amendments
F18 Inserted by Commission Regulation (EC) No 61/2003 of 15 January 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F19 Inserted by Commission Regulation (EC) No 1815/2001 of 14 September 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F20 Inserted by Commission Regulation (EC) No 2162/2001 of 7 November 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F21 Inserted by Commission Regulation (EC) No 1805/2006 of 7 December 2006 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards thiamphenicol, fenvalerate and meloxicam (Text with EEA relevance).
F22 Inserted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F23 Inserted by Commission Regulation (EC) No 1029/2003 of 16 June 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F24 Inserted by Commission Regulation (EC) No 2011/2003 of 14 November 2003 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F252.2.4. Acyl urea derivatives U.K.
a [F26Not for use in animals from which milk is produced for human consumption.] ] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F27Diflubenzuron | Diflubenzuron | Salmonidae | 1 000 μg/kg | Muscle and skin in natural proportions | ] |
[F26Fluazuron | Fluazuron | Bovine a | 200 μg/kg | Muscle | |
7 000 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
500 μg/kg | Kidney] | ||||
Teflubenzuron | Teflubenzuron | Salmonidae | 500 μg/kg | Muscle and skin in natural proportions |
Textual Amendments
F26 Inserted by Commission Regulation (EC) No 1451/2006 of 29 September 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards fluazuron, sodium nitrite and peforelin (Text with EEA relevance).
F27 Inserted by Commission Regulation (EC) No 2593/1999 of 8 December 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Textual Amendments
F25 Inserted by Commission Regulation (EC) No 1931/1999 of 9 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F282.2.5. Pyrimidines derivatives U.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Dicyclanil | Sum of dicyclanil and 2, 4, 6-triamino-pyrimidine-5-carbonitrile | Ovine | 200 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
[F29150 μg/kg] | Fat | ||||
400 μg/kg | Liver | ||||
400 μg/kg | Kidney] |
Textual Amendments
F29 Substituted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Textual Amendments
F28 Inserted by Commission Regulation (EC) No 1960/2000 of 15 September 2000 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F22.2.6. Triazine derivatives U.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Cyromazine | Cyromazine | Ovine | 300 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
300 μg/kg | Fat | ||||
300 μg/kg | Liver | ||||
300 μg/kg | Kidney] |
2.3. Agents acting against endo- and ectoparasites U.K.
2.3.1. Avermectins U.K.
a [F30Not for use in animals from which milk is produced for human consumption.] | |||||
Phramacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Abamectin | Avermectin B1a | Bovine | 10 μg/kg | Fat | |
20 μg/kg | Liver | ||||
[F12 | Ovine | 20 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption | |
50 μg/kg | Fat | ||||
25 μg/kg | Liver | ||||
20 μg/kg | Kidney | ] | |||
[F31Doramectin | Doramectin | All mammalian food producing species a | 40 μg/kg | Muscle | |
150 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
60 μg/kg | Kidney] | ||||
[F32Emamectin | Emamectin B1a | Fin fish | 100 μg/kg | Muscle and skin in natural proportions | ] |
Eprinomectin | Eprinomectin B1a | Bovine | [F3350 μg/kg] | Muscle | |
[F33250 μg/kg] | Fat | ||||
[F331 500 μg/kg] | Liver | ||||
[F33300 μg/kg] | Kidney | ||||
[F3320 μg/kg] | Milk | ||||
Ivermectin | 22, 23-Dihydro-avermectin B1a | Bovine | 40 μg/kg | Fat | |
100 μg/kg | Liver | ||||
Porcine, ovine, equidae | 20 μg/kg | Fat | |||
15 μg/kg | Liver | ||||
Deer, including reindeer | 20 μg/kg | Muscle | |||
100 μg/kg | Fat | ||||
50 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
[F34 | All mammalian food-producing species a | 100 μg/kg | Fat | ||
100 μg/kg | Liver | ||||
30 μg/kg | Kidney | ] | |||
Moxidectin | Moxidectin | Bovine, ovine | 50 μg/kg | Muscle | |
500 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
[F35 | Bovine | 40 μg/kg | Milk | ] | |
[F11 | Equidae | 50 μg/kg | Muscle | ||
500 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
50 μg/kg | Kidney | ] | |||
[F36 | Ovine | 40 μg/kg | Milk | ] |
Textual Amendments
F30 Inserted by Commission Regulation (EC) No 869/2005 of 8 June 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards ivermectin and carprofen (Text with EEA relevance).
F31 Substituted by Commission Regulation (EC) No 1831/2006 of 13 December 2006 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Doramectin (Text with EEA relevance).
F32 Substituted by Commission Regulation (EC) No 1490/2003 of 25 August 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F33 Substituted by Commission Regulation (EC) No 1943/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F34 Substituted by Commission Regulation (EC) No 869/2005 of 8 June 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards ivermectin and carprofen (Text with EEA relevance).
F35 Inserted by Commission Regulation (EC) No 1553/2001 of 30 July 2001 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F36 Inserted by Commission Regulation (EC) No 75/2005 of 18 January 2005 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards moxidectin, linear alkyl benzene sulphonic acids with alkyl chain lengths ranging from C9 to C13, containing less than 2,5 % of chains longer than C13 and Acetylisovaleryltylosin (Text with EEA relevance).
2.4. Agents acting against protozoa U.K.
2.4.1. Triazinetrione derivative U.K.
a [F37Not for use in animals from which milk is produced for human consumption. | |||||
b For porcine species this MRL relates to ‘ skin and fat in natural proportions ’ . | |||||
c Not for use in animals from which eggs are produced for human consumption.] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Toltrazuril | Toltrazuril sulfone | Chicken | 100 μg/kg | Muscle | Not for use in animals from which eggs are produced for human consumption |
200 μg/kg | Skin and fat | ||||
600 μg/kg | Liver | ||||
400 μg/kg | Kidney | ||||
Turkey | 100 μg/kg | Muscle | |||
200 μg/kg | Skin and fat | ||||
600 μg/kg | Liver | ||||
400 μg/kg | Kidney | ||||
[F38 | Porcine | 100 μg/kg | Muscle | ||
150 μg/kg | Skin and fat | ||||
500 μg/kg | Liver | ||||
250 μg/kg | Kidney | ] | |||
[F37 | All mammalian food producing species a | 100 μg/kg | Muscle | ||
150 μg/kg | Fat b | ||||
500 μg/kg | Liver | ||||
250 μg/kg | Kidney | ||||
Poultry c | 100 μg/kg | Muscle | |||
200 μg/kg | Skin + fat | ||||
600 μg/kg | Liver | ||||
400 μg/kg | Kidney | ] |
Textual Amendments
F37 Inserted by Commission Regulation (EC) No 205/2006 of 6 February 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards toltrazuril, diethylene glycol monoethyl ether and polyoxyethylene sorbitan monooleate (Text with EEA relevance).
F38 Inserted by Commission Regulation (EC) No 2908/2000 of 29 December 2000 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F382.4.2. Quinazolone derivatives U.K.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Halofuginone | Halofuginone | Bovine | 10 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
25 μg/kg | Fat | ||||
30 μg/kg | Liver | ||||
30 μg/kg | Kidney] |
[F202.4.3. Carbanilides U.K.
a [F39Not for use in ovine from which milk is produced for human consumption.] ] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Imidocarb | Imidocarb | Bovine | 300 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
2 000 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
[F39Ovine a | 300 μg/kg | Muscle | |||
50 μg/kg | Fat | ||||
2 000 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ] |
Textual Amendments
F39 Inserted by Commission Regulation (EC) No 2145/2003 of 8 December 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
[F402.4.4. Ionophores U.K.
Textual Amendments
F41 Deleted by Commission Regulation (EC) No 1353/2007 of 20 November 2007 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Monensin, Lasalocid and Tylvalosin (Text with EEA relevance).
Textual Amendments
F40 Inserted by Commission Regulation (EC) No 712/2005 of 11 May 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards lasalocid and ammonium and sodium salts of bituminosulfonates (Text with EEA relevance).
Textual Amendments